🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase I Pipeline Programs

First-in-human and early clinical safety studies in Phase I.

Programs
4,713

Quick answer

NovaPharmaNews tracks 4,713 phase i pharmaceutical pipeline programs from ClinicalTrials.gov. First-in-human and early clinical safety studies in Phase I.

Top sponsors

Page 12 of 99

  1. A study in healthy men to test whether BI 1815368 influences the amount of metformin in the body

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  2. A study in healthy men to test whether carbamazepine influences the amount of nerandomilast in the blood

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  3. A study in healthy men to test whether esomeprazole influences the amount of BI 3000202 in the blood

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  4. A study in healthy men to test whether food influences the amount of BI 3731579 in the blood

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  5. A study in healthy men to test whether zongertinib influences the amount of 3 other medicines in the blood

    Boehringer Ingelheim

    Pharmacokinetic trial

    phase 1 other active

    1 trial

  6. A study in healthy men to test whether zongertinib influences the amount of 4 other medicines (dabigatran, rosuvastatin, metformin, and furosemide) in the blood

    Boehringer Ingelheim

    Pharmacokinetic trial

    phase 1 other active

    1 trial

  7. A study in healthy people or otherwise healthy but overweight or obese to compare 2 formulations of survodutide given in different ways, either as a pre-filled syringe or a pen-like injector

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  8. A study in healthy people or otherwise healthy with overweight or obesity to compare 2 formulations of survodutide given in different ways, either as a pre-filled syringe or a pen-like injector

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  9. A study in healthy people to compare how 2 different formulations of survodutide are taken up by the body

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  10. A study in healthy people to compare how 2 different formulations of survodutide are taken up in the body

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  11. A study in healthy people to compare how 2 different high dose formulations of BI 1015550 are taken up in the body

    Boehringer Ingelheim

    Pharmacokinetic trial

    phase 1 other active

    1 trial

  12. A study in healthy people to compare how 2 different low dose formulations of BI 1015550 are taken up in the body

    Boehringer Ingelheim

    Pharmacokinetic trial

    phase 1 other active

    1 trial

  13. A study in healthy people to compare how 3 different formulations of survodutide are taken up in the body

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  14. A study in healthy people to compare two different Sifrol® tablets

    Boehringer Ingelheim

    Pharmacokinetic trial

    phase 1 other active

    1 trial

  15. A study in healthy people to compare two different tablets of BI 685509 and to test how food and esomeprazole influence the amount of BI 685509 in the blood

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  16. A study in healthy people to compare two tablet formulations of pramipexole

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  17. A study in healthy people to see how zongertinib is taken up into the blood when given as tablets made by two different manufacturers

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  18. A study in healthy people to test how 2 different doses of BI 1291583 are taken up in the body when given in 3 different formulations.

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  19. A study in healthy people to test how 2 different formulations of BI 690517 are taken up in the body and how probenecid influences the amount of BI 690517 in the blood

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  20. A study in healthy people to test how 3 different formulations of BI 764198 are taken up in the body and how this is influenced by food

    Boehringer Ingelheim

    healthy volunteer trial

    phase 1 other active

    1 trial

  21. A study in healthy people to test how BI 1015550 is taken up in the body when given with or without food

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  22. A study in healthy people to test how empagliflozin is taken up in the body when taken as a whole tablet or dissolved in water and mixed with food

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  23. A study in healthy people to test how itraconazole influences the amount of BI 3031185 in the blood

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  24. A study in healthy people to test how vicadrostat affects the heart

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  25. A study in healthy people to test how well different doses of BI 3000202 are tolerated and how they affect the way the body handles midazolam

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  26. A study in healthy people to test whether BI 1291583 influences the amount of dabigatran in the body

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  27. A study in healthy people to test whether BI 3000202 affects how 2 other medicines (rosuvastatin and digoxin) are taken up in the body

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  28. A study in healthy people to test whether BI 764198 influences the amount of metformin in the body

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  29. A study in healthy people to test whether erythromycin influences the amount of BI 1291583 in the blood.

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  30. A study in healthy subjects investigating the safety, tolerability and concentrations of FE 999301 after single and multiple doses

    Ferring Pharmaceuticals

    Inflammatory Gastrointestinal Disease

    phase 1 other active

    1 trial

  31. A study in healthy volunteers to find out how long aticaprant stays in and acts on the body when administered with or without food and with or without fluconazole

    Janssen-Cilag International N.V.

    Healthy Adult Participants

    phase 1 other active

    1 trial

  32. A study in healthy volunteers to find out how long aticaprant stays in and acts on the body when administered with or without rabeprazole.

    Janssen-Cilag International N.V.

    Healthy Adult Participants.

    phase 1 other active

    1 trial

  33. A study in patients with different types of advanced cancer (solid tumors) to test different doses of BI 907828 (brigimadlin) in combination with BI 754091 (ezabenlimab) and BI 754111 or BI 907828 (brigimadlin) in combination with BI 754091 (ezabenlimab)

    Boehringer Ingelheim

    advanced solid tumors

    phase 1 other active

    1 trial

  34. A study in people with advanced cancer (solid tumours) to test different doses of BI 3810944 and to find out whether it helps

    Boehringer Ingelheim

    Melanoma, Solid tumours

    phase 1 other active

    1 trial

  35. A study in people with advanced cancer to test how well different doses of BI 3819026 are tolerated when taken alone and together with ezabenlimab

    Boehringer Ingelheim

    unresectable advanced or metastatic solid cancer

    phase 1 other active

    1 trial

  36. A study in people with advanced cancer to test whether the amount of BI 907828 in the blood is influenced by taking an OATP inhibitor or a CYP3 inhibitor

    Boehringer Ingelheim

    Solid cancer tumors

    phase 1 other active

    1 trial

  37. A study in people with obesity to test the effects of different doses of BI 456906 compared with semaglutide on glucagon receptor activity in the liver

    Boehringer Ingelheim

    No targeted indication. Male and female subjects with obesity.

    phase 1 other active

    1 trial

  38. A study in people with overweight or obesity to test how BI 1820237, BI 456906, or a combination of both affects brain activity

    Boehringer Ingelheim

    Obesity

    phase 1 other active

    1 trial

  39. A study in subjects with gout flares that investigates the effect, safety, tolerability, and pharmacokinetics (absorption, distribution, metabolism, and elimination) of a single dose of LEO 158968, a new compound that may potentially be used in the treatment of several autoinflammatory diseases

    LEO Pharma A/S

    Gout flares

    phase 1 other active

    1 trial

  40. A study investigating the effect of different approved medications on how the body processes the study compound RO7795081. RO7795081 is a new compound that may potentially be used in the treatment of type 2 diabetes and weight control.

    Hoffmann-La Roche

    Type 2 Diabetes and obesity

    phase 1 other active

    1 trial

  41. A study investigating the safety of RO7795081 and the effect of RO7795081 on how the body processes different approved medications. RO7795081 is a new compound that may potentially be used in the treatment of type 2 diabetes and weight control

    Hoffmann-La Roche

    Obesity or Overweight

    phase 1 other active

    1 trial

  42. A study investigating the safety, absorption, and elimination of NNC0705-0001, a new compound that could potentially be used in the treatment of cardiometabolic diseases caused by inflammation.

    NovoThirteen

    Cardiometabolic diseases with an inflammatory component

    phase 1 other active

    1 trial

  43. A study investigating the safety, absorption, and elimination of RO7795068, a new compound that may potentially be used in the treatment of obesity

    Hoffmann-La Roche

    Healthy volunteers

    phase 1 other active

    1 trial

  44. A study investigating the safety, absorption, and elimination of RO7795068, a new compound that may potentially be used in the treatment of obesity

    Hoffmann-La Roche

    Not Applicable

    phase 1 other active

    1 trial

  45. A study investigating the safety, absorption, and elimination of RO7795081, a new compound that may potentially be used in the treatment of type 2 diabetes and weight control

    Hoffmann-La Roche

    Not Applicable

    phase 1 other active

    1 trial

  46. A study investigating the safety, absorption, and elimination of radioactively labeled RO7269162, a new compound that may potentially be used in the treatment of Alzheimer’s disease.

    Hoffmann-La Roche

    Healthy males volunteers

    phase 1 other active

    1 trial

  47. A study investigating the safety, tolerability, metabolism, and elimination of INE963, a new compound in the treatment of malaria.

    Novartis Pharmaceuticals

    Malaria

    phase 1 other active

    1 trial

  48. A study of ASP2138 given by itself or given with other cancer treatments in adults with stomach cancer, gastroesophageal junction cancer, or pancreatic cancer

    Astellas Pharma GmbH

    Gastroesophageal Junction (GEJ) Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma

    phase 1 other active

    1 trial

Frequently asked questions

How many Phase I pipeline programs are in the directory?

4,713 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.